MACS GMP PepTivator BKV VP1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap. It has been developed for efficient
in vitro
stimulation and subsequent isolation of BKV VP1-specific CD4
+
and CD8
+
T cells.

Specifications for
MACS
®
GMP PepTivator
®
BKV VP1

Overview

MACS GMP PepTivator BKV VP1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap. It has been developed for efficient
in vitro
stimulation and subsequent isolation of BKV VP1-specific CD4
+
and CD8
+
T cells.

Detailed product information

Background information

BKV is a ubiquitous polyomavirus. After primary infection BKV persists in a latent state. Virus reactivation might occur in immunodeficiency or during immunosuppression. VP1 is the major capsid protein of BKV, expressed late in the lytic cycle.

Applications

Adoptive transfer of BKV VP1-specific T cells may be an effective tool for the treatment of BKV-associated infections after stem cell transplantation or solid organ transplantation.
1,2
In vitro
stimulation of BKV VP1-specific CD4
+
and CD8
+
T cells with MACS GMP PepTivator BKV VP1 causes the production of the effector cytokine IFN-γ. The secretion of IFN-γ then permits the enrichment of BKV VP1-specific effector/memory T cells using the CliniMACS
®
Cytokine Capture System (IFN-gamma).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.

Resources for
MACS
®
GMP PepTivator
®
BKV VP1

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for
MACS
®
GMP PepTivator
®
BKV VP1

Publications

  1. Ramaswami B. et al. (2011)
    The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4
    +
    T-cell response.
    Clin. Vaccine Immunol. 18(5): 815-824
  2. Blyth E. et al. (2011) BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 92(10): 1077-1084

Related products for
MACS
®
GMP PepTivator
®
BKV VP1

4 products available